SFM
CORT icon

Systematic Financial Management’s Corcept Therapeutics CORT Stock Holding History

Systematic Financial Management’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-17,610
Closed -$296K – 293
2020
Q2 		$296K Sell
17,610
-18,280
-51% -$257K 0.02% 384
2020
Q1 		$427K Sell
35,890
-10,030
-22% -$124K 0.03% 198
2019
Q4 		$556K Buy
+45,920
New +$639K 0.02% 395

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Systematic Financial Management's CORT Position: Q3 2020 in Review

Systematic Financial Management sold out of Corcept Therapeutics (CORT) in Q3 2020, closing a stake of 17,610 shares — an estimated $296K sold.

Systematic Financial Management first reported a position in CORT in Q4 2019 and held it in 3 quarters. The position peaked at $556K in Q4 2019. 223 funds tracked by Wall St. Rank hold CORT as of Q3 2020.

  • Systematic Financial Management reported no remaining Corcept Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Systematic Financial Management sold 17,610 Corcept Therapeutics shares in Q3 2020, an estimated $296K.
  • Systematic Financial Management first reported a position in Corcept Therapeutics in Q4 2019 and held it in 3 quarters.
  • Systematic Financial Management's Corcept Therapeutics position peaked at $556K in Q4 2019.
  • 223 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q3 2020.

Based on Systematic Financial Management's 13F filing for Q3 2020, filed 12 Nov 2020.